

# ForPatients

by Roche

Breast Cancer Breast Cancer Er-Positive Breast Cancer HER-2 Negative

## A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

**Trial Status**

Active, not recruiting

**Trial Runs In**

5 Countries

**Trial Identifier**

NCT03332797 2017-002083-41  
GO39932

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This study will evaluate the safety, pharmacokinetic (PK), pharmacodynamic (PD) activity, and preliminary anti-tumor activity of GDC-9545 as a single agent and in combination with palbociclib and/or luteinizing hormone-releasing hormone (LHRH) agonist in participants with advanced or metastatic estrogen receptor (ER)-positive (human epidermal growth factor receptor 2 [HER2]-negative) breast cancer.

**Genentech, Inc.**

Sponsor

**Phase 1**

Phase

---

**NCT03332797 2017-002083-41 GO39932**

Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**

Female

**Age**

>= 18 Years

**Healthy Volunteers**

No

---